CN Patent

CN113648304A — 一种含达格列净的药物组合物及其制备方法和应用

Assigned to YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO Ltd · Expires 2021-11-16 · 5y expired

What this patent protects

本发明提供一种含达格列净的药物组合物及其制备方法和应用。所述含达格列净的药物组合物的制备原料包括：D90小于30μm的达格列净、乳糖、微晶纤维素、二氧化硅、羧甲淀粉钠和硬脂酸镁。本发明所述药物组合物控制原料药的D90粒径小于30μm，从而充分提高体外溶出能力；并通过对辅料的选择，在保证达格列净的稳定性的同时，可有效提高达格列净的溶出度和速率。

USPTO Abstract

本发明提供一种含达格列净的药物组合物及其制备方法和应用。所述含达格列净的药物组合物的制备原料包括：D90小于30μm的达格列净、乳糖、微晶纤维素、二氧化硅、羧甲淀粉钠和硬脂酸镁。本发明所述药物组合物控制原料药的D90粒径小于30μm，从而充分提高体外溶出能力；并通过对辅料的选择，在保证达格列净的稳定性的同时，可有效提高达格列净的溶出度和速率。

Drugs covered by this patent

Patent Metadata

Patent number
CN113648304A
Jurisdiction
CN
Classification
—
Expires
2021-11-16
Drug substance claim
No
Drug product claim
No
Assignee
YANGZIJIANG PHARMACEUTICAL GROUP SHANGHAI HAINI PHARMACEUTICAL CO Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.